JOURNAL ARTICLE

Intensive Antihypertensive Treatment and Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.

  • Published In: European Neurology, 2025, v. 88, n. 3/4. P. 129 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Liao, Ziwei; Cheng, Liping; Wang, Yining; Yang, Yanjuan; Lv, Xiaoxian; Gu, Ping 3 of 3

Abstract

Introduction: Hypertension is a significant risk factor for the development of cerebral small vessel disease (SVD). This study was performed to evaluate the impact of intensive antihypertensive treatment on the progression of imaging markers and cognitive function of SVD. Methods: Two independent reviewers searched for randomised controlled trials (RCTs) that investigated the associations between intensive antihypertensive treatment and the progression of imaging markers of SVD, including white matter hyperintensities (WMHs), brain atrophy, lacunes, or microbleeds and cognitive function scores. Fixed-effects models were used to pool the data for WMHs, brain atrophy, and severe adverse events, whereas cognitive function scores were synthesised with a random-effects model and were measured as standardised mean differences (SMDs) and odds ratios (ORs). Results: A total of 8 RCTs were included in this meta-analysis, involving 2,891 participants with a follow-up period of 24 to 49 months. Compared with standard blood pressure treatment, intensive antihypertensive treatment was observed to be more effective at delaying WMH progression (SMD = −0.33, 95% CI: −0.44, −0.21) but was associated with greater brain volume loss (SMD = 4.06, 95% CI: 1.97, 6.15). No increased risk of incident lacunes (OR = 1.11, 95% CI: 0.57, 2.19) or significant association with cognitive function changes (SMD = −0.08, 95% CI: −0.23, 0.06) was observed. However, the pooled analysis of cerebral microbleeds was limited by the small number of eligible studies included in this meta-analysis. Conclusion: Antihypertensive treatment (particularly intensive therapy) is associated with reductions in the progression of WMH volume and total brain volume. However, no significant association was observed between antihypertensive therapy and either the incidence of new lacunes or changes in cognitive function. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:European Neurology. 2025/05, Vol. 88, Issue 3/4, p129
  • Document Type:Literature Review
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • ISSN:0014-3022
  • DOI:10.1159/000547434
  • Accession Number:189168525
  • Copyright Statement:Copyright of European Neurology is the property of Karger AG and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.